Abstract

BackgroundExtracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in Germany in ECLS therapy did not differ from previously reported literatureMethodsInpatient data from Germany from 2007 to 2018 provided by the Federal Statistical Office of Germany were analysed. The international statistical classification of diseases and related health problems codes (ICD) and process keys (OPS) for extracorporeal membrane oxygenation (ECMO) types, acute respiratory distress syndrome (ARDS) and hospital mortality were used.ResultsIn total, 45,647 hospitalized patients treated with ECLS were analysed. In Germany, 231 hospitals provided ECLS therapy, with a median of 4 VV-ECMO and 9 VA-ECMO in 2018. Overall hospital mortality remained higher than predicted in comparison to the values reported in the literature. The number of VV-ECMO cases increased by 236% from 825 in 2007 to 2768 in 2018. ARDS was the main indication for VV-ECMO in only 33% of the patients in the past, but that proportion increased to 60% in 2018. VA-ECMO support is of minor importance in the treatment of ARDS in Germany. The age distribution of patients undergoing ECLS has shifted towards an older population. In 2018, the hospital mortality decreased in VV-ECMO patients and VV-ECMO patients with ARDS to 53.9% (n = 1493) and 54.4% (n = 926), respectively.ConclusionsARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization (ELSO) Registry, the reported mortality in these studies was lower than in the present analysis. Further prospective analyses are necessary to evaluate outcomes in ECMO therapy at the centre volume level.

Highlights

  • Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy

  • Venovenous‐extracorporeal membrane oxygenation (ECMO) The number of VV-ECMO cases increased by 236% from 825 in 2007 to 2768 in 2018

  • In 2018, the hospital mortality decreased in VV-ECMO patients and VV-ECMO patients with acute respiratory distress syndrome (ARDS) to 53.9% (n = 1493) and 54.4% (n = 926), respectively

Read more

Summary

Introduction

Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. Various pulmonary and cardiac conditions are indications for the use of ECLS [1]. Different terms are used in the literature for ECLS depending on the system and type of cannulation. ECMO is further classified into venoarterial-ECMO (VA-ECMO) and venovenous-ECMO (VV-ECMO), depending on the support mode. Patients who have undergone lung replacement due to respiratory failure are mainly treated with VV-ECMO, but the cannulation strategy is Friedrichson et al Crit Care (2021) 25:38 often venoarterial (VA) or venovenoarterial (VVA) for patients with combined cardiac and pulmonary failure. VA cannulation is used for cardiac support and is useful for cardiac and cardiosurgical indications as well as for extracorporeal cardiopulmonary resuscitation (E-CPR). The choice of support mode depends largely on the indication. We hypothesized that mortality in Germany in ECLS therapy did not differ from previously reported literature

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call